Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
Clinical trial NCT03226678 · COMPLETED
Trial details
- NCT number
- NCT03226678
- Sponsor
- Apellis Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-31
- Primary completion
- 2022-09-12
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.